# Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML

> **NCT02461537** · PHASE3 · COMPLETED · sponsor: **DKMS gemeinnützige GmbH** · enrollment: 281 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** HAM
- **DRUG:** LDAC and/or Mitoxantrone

## Key facts

- **NCT ID:** NCT02461537
- **Lead sponsor:** DKMS gemeinnützige GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-17
- **Primary completion:** 2022-04-05
- **Final completion:** 2024-01-12
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461537, "Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02461537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*